Many report no serious issues
2 Foundayo is an oral GLP-1 receptor agonist that was FDA-approved April 1, 2026, for adults with obesity or who are overweight with at least one weight-related comorbidity
It is indicated for weight management for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease Zepbound comes in either a single-use pen or a single-dose vial that you would use with a needle and syringe
NRF2 regulates the expression of enzymes in both the oxidative (G6PD and PGD) and non-oxidative (TKT and TALDO1) arms of the PPP [58]
Lotte Bjerre Knudsen (24:34): So I'm not sure we can say that it comes before the weight loss because the energy intake reduction happens instantly
3 An initial evaluation by the FDA suggests no direct link between GLP-1 medications and suicidal ideation